Text Size Normal Text Sizing Button Medium Text Sizing Button Large Text Sizing Button Text Contrast Normal Contrast Button Reverse Contrast Button Switch to Spanish Language Press Room Contact Us Sitemap Sign In Register
Link to Homepage About BrightFocus
BrightFocus
Donate Now Get Involved  
Alzheimer's Disease Research Macular Degeneration Research National Glaucoma Research


Sign up for Email Notifications
If you would like to be notified when funding or meeting opportunities are announced please click on the link below.

Sign up for new announcements.

This email list is not sold or distributed, and serves only as an annual reminder of the availability of research support through the BrightFocus Foundation (www.brightfocus.org). Please follow instructions on the notification emails for removal requests.

 
 
BrightFocus Research Grants Funding
Grant Funding for Alzheimer's Research
Grant Funding for Macular Degeneration Research
Grant Funding for Glaucoma Research
 

 

National Glaucoma Research
Completed Award

Photo Pending

Hiroshi Nakamura, M.D., Ph.D.

Summa Health System
Akron, OH

Title: Suppression of Ocular Scarring by RNA Interference
Non-Technical Title: Preventing scarring to reduce complications from glaucoma surgeries

Duration: April 1, 2006 - March 31, 2009
Award Type: Standard
Award Amount: $90,000

Summary:

This project proposes to employ RNA interference (RNAi) technology to target CTGF. It is hoped that silencing of the growth factor will help block the scarring action. The efficacy and consequence of the siRNAs will be studied in cultured conjunctival fibroblasts.

Details:

Connective tissue growth factor (CTGF) is an important mediator of wound healing in various tissues. In the eye, CTGF has been implicated in corneal wound healing, and subconjunctival scarring following glaucoma surgery. This project proposes to employ RNA interference (RNAi) technology to target CTGF. It is hoped that silencing of the growth factor will help block the scarring action. The efficacy and consequence of the siRNAs will be studied in cultured conjunctival fibroblasts. Investigation in an ocular inflammation/fibrosis model in mouse will be followed to determine whether downregulation of CTGF would reduce inflammation and scarring. The current proposal is highly significant for its clinical impact since excessive scarring is often a major cause of impaired vision and blindness. Results obtained from this application may lead to novel therapeutic modalities to prevent inflammation and scarring after glaucoma surgery and in eye diseases including corneal opacities.